SCHEMBL20599735

SCHEMBL20599735

COC(=O)CC(=O)C1CCC(C(=O)OC)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.43
GAA P10253 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MGAM O43451 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
CHRNB2 P17787 2/20 0.38
CHRNA4 P43681 2/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA7 P36544 1/20 0.38
ALDH1A1 P00352 4/20 0.38
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.37
PPM1B O75688 1/20 0.36
PTPN1 P18031 1/20 0.36
PPP1CC P36873 1/20 0.36
HTT P42858 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21987187 1.00 TP53 (0.43) TP53GAASMN1; SMN2MGAMSI
SCHEMBL20599527 0.94 SMN1; SMN2 (0.45) TP53GAASMN1; SMN2MGAMSI
SCHEMBL221809 0.91 GAA (0.46) GAASMN1; SMN2MGAMSIMGAM2
SCHEMBL20599690 0.88 CHRNB2 (0.40) TP53GAASMN1; SMN2MGAMSI
SCHEMBL2680543 0.85 GAA (0.51) TP53GAASMN1; SMN2MGAMSI
SCHEMBL10236626 0.85 GAA (0.51) TP53GAASMN1; SMN2MGAMSI
SCHEMBL16732426 0.83 SMN1; SMN2 (0.41) TP53GAASMN1; SMN2CHRNB2CHRNA4
SCHEMBL16732424 0.83 SMN1; SMN2 (0.41) TP53GAASMN1; SMN2CHRNB2CHRNA4
SCHEMBL21987526 0.83 CHRNB2 (0.47) TP53GAASMN1; SMN2MGAMSI
SCHEMBL15634828 0.83 GAA (0.47) TP53GAASMN1; SMN2CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11639350-B2 Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections JANSSEN PHARMACEUTICA NV (BE) 2023-05-02 US disclosed
US-20200172532-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2020-06-04 US disclosed
EP-3645516-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS Janssen Pharmaceutica NV (BE) 2020-05-06 EP disclosed
CN-110809574-A Heteroaryl dihydropyrimidine derivatives and methods for treating hepatitis b infection 詹森药业有限公司 2020-02-18 CN disclosed
WO-2019001420-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200172532-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS HAVCR2, HCCS, PYGL TP53 513/4885GAA 1238/4885SMN1; SMN2 4696/4885
US-11639350-B2 Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections HCCS, HAVCR2, NR1H4 TP53 1398/4885GAA 2071/4885SMN1; SMN2 4624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.